Baiyunshan's Subsidiary Receives Clinical Trial Approval for Shujin Jianyao Pill
Stock News
4 hours ago
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (600332.SH) has announced that its subsidiary, Guangzhou Baiyunshan Chenliji Pharmaceutical Factory Co., Ltd. (referred to as "Chenliji Pharmaceutical Factory"), recently received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration regarding the addition of new indications for Shujin Jianyao Pill.
The approval permits the product to conduct clinical trials for the treatment of lumbar disc herniation with liver-kidney deficiency syndrome and wind-dampness obstruction syndrome.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.